Mepolizumab, a humanized monoclonal antibody to IL-5, for severe eosinophilic Esophagitis in adults: A randomized, placebo-controlled double-blind trial

被引：11
|
作者：
Straumann, A. [1 ]
Conus, S. [2 ]
Kita, H. [3 ]
Kephart, G. [3 ]
Bussmann, C. [4 ]
Beglinger, C. [5 ]
Patel, J. [6 ]
Byrne, M. [6 ]
Simon, H. U. [2 ]
机构：
[1] FMH Gastroenterol, Olten, Switzerland
[2] Univ Bern, Dept Pharmacol, CH-3012 Bern, Switzerland
[3] Mayo Clin, Dept Med, Div Allerg Dis, Rochester, MN USA
[4] Viollier Lab, Basel, Switzerland
[5] Univ Basel, Dept Gastroenterol, CH-4003 Basel, Switzerland
[6] GlaxoSmithKline Inc, Greenford, Middx, England
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2008年 / 121卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2007.12.179
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
171
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 50 条
  • [1] Mepollzumab, a humanized monoclonal antibody to IL-5, for severe eosinophilic esophagitis in adults: A randomized, placebo-controlled double-blind trial
    Straumann, A.
    Conus, S.
    Simon, H.
    Kita, H.
    Kephart, G.
    Bussmann, C.
    Beglinger, C.
    Patel, J.
    Byrne, M.
    GASTROENTEROLOGY, 2007, 132 (07) : 2586 - 2586
  • [2] The Pharmacodynamic Effects of Mepolizumab, a Humanized Monoclonal Antibody Against IL-5, in Pediatric Patients with Eosinophilic Esophagitis: A Randomized, Double-blind, Controlled Clinical Trial
    Assa'ad, A.
    Aceves, S.
    Gupta, S.
    Drouin, E.
    Collins, M.
    Jurgensen, C.
    Heath, A.
    Perschy, T.
    Patel, J.
    Ortega, H.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (02) : AB129 - AB129
  • [3] Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
    Pavord, Ian D.
    Korn, Stephanie
    Howarth, Peter
    Bleecker, Eugene R.
    Buhl, Roland
    Keene, Oliver N.
    Ortega, Hector
    Chanez, Pascal
    LANCET, 2012, 380 (9842): : 651 - 659
  • [4] A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis
    Konikoff, Michael R.
    Noel, Richard J.
    Blanchard, Carine
    Kirby, Cassie
    Jameson, Sean C.
    Buckmeier, Bridget K.
    Akers, Rachel
    Cohen, Mitchell B.
    Collins, Margaret H.
    Assa'ad, Amal H.
    Aceves, Seema S.
    Putnam, Philip E.
    Rothenberg, Marc E.
    GASTROENTEROLOGY, 2006, 131 (05) : 1381 - 1391
  • [5] Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial
    Spergel, Jonathan M.
    Rothenberg, Marc E.
    Collins, Margaret H.
    Furuta, Glenn T.
    Markowitz, Jonathan E.
    Fuchs, George, III
    O'Gorman, Molly A.
    Abonia, Juan Pablo
    Young, James
    Henkel, Timothy
    Wilkins, H. Jeffrey
    Liacouras, Chris A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : 456 - U275
  • [6] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY RPC4046 IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS
    Hirano, I.
    Collins, M.
    Assouline-Dayan, Y.
    Evans, L.
    Gupta, S.
    Schoepfer, A.
    Straumann, A.
    Rodriguez, C.
    Hua, S.
    Dellon, E.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S15 - S15
  • [7] Safety and tolerability of anti-IL-5 monoclonal antibody (Mepolizumab) therapy in patients with HES: A multicenter, randomized, double-blind, placebo-controlled trial.
    Klion, Amy D.
    Rothenberg, Marc E.
    Murray, John J.
    Singh, Anish
    Simon, Hans-Uwe
    BLOOD, 2006, 108 (11) : 762A - 762A
  • [8] MEPOLIZUMAB IMPROVES HISTOLOGIC SEVERITY AS MEASURED BY THE EOE-HSS IN ADOLESCENS AND ADULTS WITH EOSINOPHILIC ESOPHAGITIS IN A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL
    Maniaci, Joseph
    Iuga, Alina
    Bookhout, Christine E.
    Cortright, Lindsay M.
    Walker, Kacie B.
    Moist, Susan E.
    Peterson, Kathryn A.
    Mitlyng, Benjamin L.
    Hirano, Ikuo
    Dellon, Evan S.
    GASTROENTEROLOGY, 2024, 166 (05) : S417 - S417
  • [9] Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial
    Straumann, A.
    Conus, S.
    Grzonka, P.
    Kita, H.
    Kephart, G.
    Bussmann, C.
    Beglinger, C.
    Smith, D. A.
    Patel, J.
    Byrne, M.
    Simon, H-U
    GUT, 2010, 59 (01) : 21 - 30
  • [10] Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial
    Dellon, Evan S.
    Peterson, Kathryn A.
    Mitlyng, Benjamin L.
    Iuga, Alina
    Bookhout, Christine E.
    Cortright, Lindsay M.
    Walker, Kacie B.
    Gee, Timothy S.
    McGee, Sarah J.
    Cameron, Brenderia A.
    Galanko, Joseph A.
    Woosley, John T.
    Eluri, Swathi
    Moist, Susan E.
    Hirano, Ikuo
    GUT, 2023, 72 (10) : 1828 - 1837
12345